ArticleBrain & spine2025
Surgical efficacy and survival outcomes of fluorescein sodium-guided surgery in glioblastoma: a single-center experience.
Article in Brain & spine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Fluorescence-guided versus non-fluorescence-guided resection in high-grade glioma: a systematic review and meta-analysis of survival outcomes.Neurosurgical review · 2026Pooled it
- Intraoperative technological advances and new frontiers in precision glioma surgery.Journal of neuro-oncology · 2026Review
- Comparison of Fluorescent Probes for IDH-Wildtype Glioblastoma, Metastatic Brain Tumors, and PCNSL: A Biomechanical Perspective.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Fluorescence-guided (FG) surgery enhances the extent of resection (EOR) in glioblastoma. While 5-aminolevulinic acid (5-ALA) is the current standard, fluorescein sodium (FS) has emerged as a promising, accessible alternative. This study evaluates the impact of FS-guided resection on surgical outcomes and survival compared to conventional white-light (WL) resection. Research question: Does FS-guided surgery improve EOR, overall survival (OS), and progression-free survival (PFS) compared to WL-guided glioblastoma surgery? Material and methods: In this retrospective single-center analysis, data from patients with newly diagnosed glioblastoma who underwent primary resection with gross total resection (GTR) intent between 2013 and 2023 were evaluated. Based on intraoperative technique, patients were allocated to either FS-guided or WL-guided surgery groups. Logistic and linear regression assessed FS impact on GTR and residual tumor volume. Multivariate Cox regression and Kaplan-Meier analysis were used to assess OS and PFS. Results: Among 128 patients, 85 (66 %) underwent FS-guided surgery. GTR was achieved in 69 % of FS cases versus 36 % with WL (p = 0.0004; OR = 1.379). FS significantly reduced residual tumor volume (1.82 ml vs. 8.83 ml; p = 0.0003). MGMT methylation, GTR, and Stupp-protocol therapy were identified as independent predictors of improved OS and PFS. FS use itself showed no significant association with survival outcomes. Discussion and conclusion: FS-guided surgery significantly improved EOR and reduced residual tumor volume without impacting OS or PFS. It represents a safe, effective alternative to standard WL resection. Prospective studies should explore combining fluorophores for optimal resection strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.